SANA · Sana Biotechnology, Inc.
$3.85
-0.07 (-1.79%)
At close · Sep 4
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that our present capital resources may not be sufficient to fund our planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$1.15B
Shares
299.36M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$244.17M
+8.5%
FY2025
Diluted EPS
-$0.96
+17.2%
FY2025
Operating Cash Flow
-$143.83M
+35.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $124.48M | $131.98M | $215.67M | $261.81M | $285.89M | $248.63M | $132.94M | $99.59M | |
| $44.71M | $44.3M | $64.04M | $73.3M | $71.56M | $50.41M | $28.27M | $21.78M | |
| — | $0 | $0 | $0 | $0 | $0 | — | — | |
| $218.75M | $250.32M | $272.72M | $293.14M | $272.56M | $356.91M | $286.15M | $141.15M | |
| -$218.75M | -$250.32M | -$272.72M | -$293.14M | -$272.56M | -$356.91M | -$286.15M | -$141.15M | |
| $2.57M | $2.31M | -$4.51M | -$52K | -$674K | $305K | $97K | -$29K | |
| — | — | — | — | — | -$355.93M | -$285.31M | -$138.33M | |
| — | $0 | — | — | — | — | — | -$7.55M | |
| -$211.82M | -$244.17M | -$266.76M | -$283.26M | -$269.48M | -$355.93M | -$285.31M | -$130.78M | |
| -$211.89M | -$244.15M | -$266.69M | -$278.99M | -$272.44M | -$357.32M | -$285.3M | -$130.75M | |
| USD/shares | -$0.75 | -$0.96 | -$1.16 | -$1.46 | -$1.43 | -$2.14 | -$21.92 | — |
| USD/shares | -$0.75 | -$0.96 | -$1.16 | -$1.46 | -$1.43 | -$2.14 | -$21.92 | — |
| shares | — | 253.23M | 230.89M | 194.54M | 188.34M | 166.43M | 13.01M | 4.9M |
| shares | — | 253.23M | 230.89M | 194.54M | 188.34M | 166.43M | 13.01M | 4.9M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 8.17×
EV/EBIT
—
Peer median 10.56×
P/E (TTM)
—
Peer median 16.91×
Peer medians compare against the 288 similar-size Biotechnology companies (of 537 listed).
Key facts
CIK
1770121
CUSIP
799566104
13F (30d)
142 filings
141 filers
Visit website
Investor relations